Piper Sandler upgraded shares of CytomX Therapeutics (NASDAQ:CTMX – Free Report) from a neutral rating to an overweight rating in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage currently has $3.50 price target on the biotechnology company’s stock, up from their prior price target of $2.25. Several other equities analysts have also […]